Aurobindo Pharma Limited

Aurobindo Pharma Ltd rose for a fifth straight session today. The stock is quoting at Rs 1678.7, up 1.13% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 23102.8. The Sensex is at 74677.67, up 0.71%. Aurobindo Pharma Ltd has added around 0.11% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has added around 3.43% in last one month and is currently quoting at 26710.8, up 1.88% on the day. The volume in the stock stood at 4.85 lakh shares today, compared to the daily average of 8.18 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1684, up 1.76% on the day. Aurobindo Pharma Ltd is up 47.4% in last one year as compared to a 10.18% fall in NIFTY and a 22.72% fall in the Nifty Pharma index.The PE of the stock is 36.54 based on TTM earnings ending June 26.

Aurobindo Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 1646.5, up 1.17% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.19% on the day, quoting at 22705.75. The Sensex is at 73339.6, down 0.35%. Aurobindo Pharma Ltd has dropped around 3.02% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has dropped around 1.54% in last one month and is currently quoting at 26267.25, up 0.96% on the day. The volume in the stock stood at 3.3 lakh shares today, compared to the daily average of 8.88 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1655, up 1.65% on the day. Aurobindo Pharma Ltd is up 48.11% in last one year as compared to a 12.85% drop in NIFTY and a 18.23% drop in the Nifty Pharma index.The PE of the stock is 36.06 based on TTM earnings ending June 26.

Aurobindo Pharma Ltd. will hold a board meeting on Wednesday, November 4, 2026, to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended September 30, 2026, and to decide on the payment of an interim dividend, if any, for the financial year 2026-27. The trading window for the company will remain closed until November 6, 2026, and will reopen on November 7, 2026, following the disclosure of the unaudited financial results.

Aurobindo Pharma Limited, in a filing on October 5, 2026, certified that details of dematerialized and rematerialized securities for the quarter ended September 30, 2026, have been furnished to the National Stock Exchange of India Limited and BSE Limited, as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, with confirming letters from KFin Technologies Limited dated October 1, 2026, enclosed for reference.

Aurobindo Pharma Limited announced that its wholly owned subsidiary, A1 USA Inc., has acquired 100% ownership of A1 Biochem Labs LLC for a cash consideration of USD 15.247 million, completing the acquisition on October 2, 2026. A1 Biochem Labs LLC, incorporated in September 2015 and based in Wilmington, North Carolina, provides contract research and chemistry services to pharmaceutical and biotechnology companies and reported USD 9.23 million in sales for the year ending December 31, 2024, and USD 5.92 million for the year ending December 31, 2025; the transaction aligns with Aurobindo’s strategic objective of expanding its presence in the Active Pharmaceutical Ingredients (API) business and creating a Contract Research, Development and Manufacturing (CRDMO) platform.

Aurobindo Pharma Limited disclosed that Apitoria Pharma Private Limited, its wholly owned subsidiary, has completed the allotment of securities to Dr. Rajendra Gadikota, the former promoter of A1 Biochem group, resulting in him holding a 20% stake in A1 Biochem Labs (India) Private Limited on a fully diluted basis. The allotment included 89,94,500 equity shares and 2,41,05,500 Compulsory Convertible Debentures, totaling Rs 33.80 crore, and means A1 Labs is no longer a wholly-owned subsidiary, although it remains a subsidiary of Apitoria and Aurobindo Pharma.

Aurobindo Pharma Limited informed the National Stock Exchange of India Limited and BSE Limited that the trading window for dealing in the company's securities will be closed for designated persons, including promoters, directors, and employees, from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the second quarter and half year ending September 30, 2026.

Aurobindo Pharma Limited announced that its step-down subsidiary, A1 Biochem Labs (India) Private Limited, subscribed to 10,000 equity shares of USD 100 each, totaling USD 1,000,000, in A1 Biochem USA Inc. in the USA on September 11, 2026, as part of the acquisition of the A1 Biochem Group previously disclosed on July 23, 2026.

Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1679.8, up 1.19% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.52% on the day, quoting at 23654.75. The Sensex is at 75645.03, down 0.64%. Aurobindo Pharma Ltd has gained around 1.93% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 1.48% in last one month and is currently quoting at 26675.5, up 0.74% on the day. The volume in the stock stood at 7.97 lakh shares today, compared to the daily average of 8.27 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1687.1, up 1.32% on the day. Aurobindo Pharma Ltd is up 60.92% in last one year as compared to a 4.88% slide in NIFTY and a 21.86% slide in the Nifty Pharma index.The PE of the stock is 36.61 based on TTM earnings ending June 26.

Aurobindo Pharma Limited announced that its wholly-owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly-owned subsidiary, Avogent Lifesciences Private Limited, in India on August 31, 2026, with an initial subscribed share capital of Rs 50,00,00,000 divided into 50,00,000 equity shares of Rs 10 each.